AVTX
Avalo Therapeutics, Inc.Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 3, 4 and 5. Form 4 must be filed within two business days of the trade.
Insider Sentiment Score
Peer-relative 0–100 rank of how aggressively insiders accumulated over the trailing 90 days. See the full ranking.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2026-06-30 | Doyle Mittie |
Director |
Sell↓
Filing footnotes — Common Stock (Direct)
The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025. |
Common Stock
|
4,654 |
| 2026-06-30 | Doyle Mittie |
Director |
Convert↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025. The stock option vests twenty-five percent (25%) on January 28, 2026 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on each such vesting date. |
Stock Option (Right to Buy)
|
1,779 |
| 2026-06-30 | Doyle Mittie |
Director |
Convert↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025. The stock option vests twenty-five percent (25%) on July 15, 2025 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on each such vesting date. |
Stock Option (Right to Buy)
|
2,875 |
| 2026-06-30 | Philip Ron M |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The options were granted on June 30, 2026, and are 100% vested. |
Stock Option (Right to Buy)
|
69 |
| 2026-06-30 | Jain Rita |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The options were granted on June 30, 2026, and are 100% vested. |
Stock Option (Right to Buy)
|
1,080 |
| 2026-06-30 | Doyle Mittie |
Director |
Convert↑
Filing footnotes — Common Stock (Direct)
The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025. |
Common Stock
|
2,875 |
| 2026-06-30 | Lind Kevin Robert |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The options were granted on June 30, 2026, and are 100% vested. |
Stock Option (Right to Buy)
|
1,105 |
| 2026-06-30 | Doyle Mittie |
Director |
Convert↑
Filing footnotes — Common Stock (Direct)
The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025. |
Common Stock
|
1,779 |
| 2026-06-23 | Doyle Mittie |
Director |
Convert↑
Filing footnotes — Common Stock (Direct)
The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025. |
Common Stock
|
1,450 |
| 2026-06-23 | Philip Ron M |
Director |
Other↑
|
No Securities Owned
|
0 |
| 2026-06-23 | Philip Ron M |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The stock option vests in three substantially equal annual installments on the first, second and third anniversary of the date of grant, subject to the Eligible Director's continued service on each such vesting date. |
Stock Option (Right to Buy)
|
40,200 |
| 2026-06-23 | Doyle Mittie |
Director |
Sell↓
Filing footnotes — Common Stock (Direct)
The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025. |
Common Stock
|
1,450 |
| 2026-06-23 | Doyle Mittie |
Director |
Convert↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025. The stock option vests twenty-five percent (25%) on January 28, 2026 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on each such vesting date. |
Stock Option (Right to Buy)
|
1,450 |
| 2026-06-10 | Doyle Mittie |
Director |
Tax↓
Filing footnotes — Common Stock (Direct)
Includes 5,738 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan as a part of this reporting transaction. |
Common Stock
|
1,084 |
| 2026-06-10 | VARKI PAUL |
Chief Legal Officer |
Tax↓
Filing footnotes — Common Stock (Direct)
Includes 5,723 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan as a part of this reporting transaction. |
Common Stock
|
1,081 |
| 2026-06-10 | Sullivan Christopher Ryan |
Chief Financial Officer |
Tax↓
Filing footnotes — Common Stock (Direct)
Includes 588 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan as a part of this reporting transaction. |
Common Stock
|
138 |
| 2026-06-10 | Riley Jennifer |
Chief Strategy Officer |
Tax↓
Filing footnotes — Common Stock (Direct)
Includes 3,429 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan as a part of this reporting transaction. |
Common Stock
|
588 |
| 2026-06-02 | Truex Samantha |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The stock option vests 100% on the first anniversary of the date of grant, subject to the director's continued service on such vesting date. |
Stock Option (Right to Buy)
|
20,100 |
| 2026-06-02 | KAPLAN GILLA |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The stock option vests 100% on the first anniversary of the date of grant, subject to the director's continued service on such vesting date. |
Stock Option (Right to Buy)
|
20,100 |
| 2026-06-02 | Heffernan Michael Thomas |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The stock option vests 100% on the first anniversary of the date of grant, subject to the director's continued service on such vesting date. |
Stock Option (Right to Buy)
|
29,500 |
| 2026-06-02 | KANTOFF AARON |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The stock option vests 100% on the first anniversary of the date of grant, subject to the director's continued service on such vesting date. |
Stock Option (Right to Buy)
|
20,100 |
| 2026-06-02 | Lind Kevin Robert |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The stock option vests 100% on the first anniversary of the date of grant, subject to the director's continued service on such vesting date. |
Stock Option (Right to Buy)
|
20,100 |
| 2026-06-02 | Jain Rita |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The stock option vests 100% on the first anniversary of the date of grant, subject to the director's continued service on such vesting date. |
Stock Option (Right to Buy)
|
20,100 |
| 2026-05-28 | Doyle Mittie |
Director |
Convert↑
Filing footnotes — Common Stock (Direct)
The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025. |
Common Stock
|
679 |
| 2026-05-28 | Doyle Mittie |
Director |
Convert↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025. The stock option vests twenty-five percent (25%) on January 28, 2026 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on each such vesting date. |
Stock Option (Right to Buy)
|
679 |
| 2026-05-28 | Doyle Mittie |
Director |
Sell↓
Filing footnotes — Common Stock (Direct)
The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025. |
Common Stock
|
679 |
| 2026-05-21 | Sullivan Christopher Ryan |
Chief Financial Officer |
Award↑
Filing footnotes — Common Stock (Direct)
Represents performance stock units ("PSUs") granted to the Reporting Person on August 19, 2025. Each PSU represents a contingent right to receive one share of the Issuer's Common Stock upon the achievement of certain performance goals. On May 21, 2026, the Compensation Committee of the Issuer certified achievement of such performance goals. As a result, the shares subject to the PSUs shall fully vest on August 19, 2028, subject to the Reporting Person's continued service on such vesting date. |
Common Stock
|
39,900 |
| 2026-05-21 | Doyle Mittie |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Represents performance stock units ("PSUs") granted to the Reporting Person on August 19, 2025. Each PSU represents a contingent right to receive one share of the Issuer's Common Stock upon the achievement of certain performance goals. On May 21, 2026, the Compensation Committee of the Issuer certified achievement of such performance goals. As a result, the shares subject to the PSUs shall fully vest on August 19, 2028, subject to the Reporting Person's continued service on such vesting date. |
Common Stock
|
43,500 |
| 2026-05-21 | NEIL GARRY ARTHUR |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Represents performance stock units ("PSUs") granted to the Reporting Person on August 19, 2025. Each PSU represents a contingent right to receive one share of the Issuer's Common Stock upon the achievement of certain performance goals. On May 21, 2026, the Compensation Committee of the Issuer certified achievement of such performance goals. As a result, the shares subject to the PSUs shall fully vest on August 19, 2028, subject to the Reporting Person's continued service on such vesting date. |
Common Stock
|
100,200 |
| 2026-05-21 | Riley Jennifer |
Chief Strategy Officer |
Award↑
Filing footnotes — Common Stock (Direct)
Represents performance stock units ("PSUs") granted to the Reporting Person on August 19, 2025. Each PSU represents a contingent right to receive one share of the Issuer's Common Stock upon the achievement of certain performance goals. On May 21, 2026, the Compensation Committee of the Issuer certified achievement of such performance goals. As a result, the shares subject to the PSUs shall fully vest on August 19, 2028, subject to the Reporting Person's continued service on such vesting date. |
Common Stock
|
34,200 |
| 2026-05-21 | VARKI PAUL |
Chief Legal Officer |
Award↑
Filing footnotes — Common Stock (Direct)
Represents performance stock units ("PSUs") granted to the Reporting Person on August 19, 2025. Each PSU represents a contingent right to receive one share of the Issuer's Common Stock upon the achievement of certain performance goals. On May 21, 2026, the Compensation Committee of the Issuer certified achievement of such performance goals. As a result, the shares subject to the PSUs shall fully vest on August 19, 2028, subject to the Reporting Person's continued service on such vesting date. |
Common Stock
|
24,300 |
| 2026-05-15 | Doyle Mittie |
Director |
Sell↓
Filing footnotes — Common Stock (Direct)
The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025. |
Common Stock
|
3,000 |
| 2026-05-15 | Doyle Mittie |
Director |
Convert↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025. The stock option vests twenty-five percent (25%) on July 15, 2025 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on each such vesting date. |
Stock Option (Right to Buy)
|
3,000 |
| 2026-05-15 | Doyle Mittie |
Director |
Convert↑
Filing footnotes — Common Stock (Direct)
The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025. |
Common Stock
|
3,000 |
| 2026-05-07 | Sullivan Christopher Ryan |
Chief Financial Officer |
Convert↑
Filing footnotes — Common Stock (Direct)
The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2025. |
Common Stock
|
18,606 |
| 2026-05-07 | Sullivan Christopher Ryan |
Chief Financial Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2025. The reported securities were sold in multiple transactions at prices ranging from $24.05 to $24.23. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. |
Common Stock
|
18,606 |
| 2026-05-07 | Sullivan Christopher Ryan |
Chief Financial Officer |
Convert↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2025. The stock option vests 25% on March 28, 2025, and 1/36 monthly thereafter, subject to the Reporting Person's continued service on such vesting date. |
Stock Option (Right to Buy)
|
18,606 |
| 2026-05-06 | VARKI PAUL |
Chief Legal Officer |
Convert↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2025. The stock option vests twenty-five percent (25%) on January 28, 2026 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on such vesting date. |
Stock Option (Right to Buy)
|
12,563 |
| 2026-05-06 | VARKI PAUL |
Chief Legal Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2025. The reported securities were sold in multiple transactions at prices ranging from $22.15 to $22.88. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. |
Common Stock
|
9,253 |
| 2026-05-06 | Doyle Mittie |
Director |
Sell↓
Filing footnotes — Common Stock (Direct)
The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025. The reported securities were sold in multiple transactions at prices ranging from $21.83 to $22.80. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. |
Common Stock
|
19,015 |
| 2026-05-06 | Sullivan Christopher Ryan |
Chief Financial Officer |
Convert↑
Filing footnotes — Common Stock (Direct)
The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2025. |
Common Stock
|
47,000 |
| 2026-05-06 | VARKI PAUL |
Chief Legal Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2025. The reported securities were sold in multiple transactions at prices ranging from $20.75 to $21.69. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. |
Common Stock
|
22,839 |
| 2026-05-06 | Sullivan Christopher Ryan |
Chief Financial Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2025. The reported securities were sold in multiple transactions at prices ranging from $19.02 to $19.91. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. |
Common Stock
|
12,347 |
| 2026-05-06 | Sullivan Christopher Ryan |
Chief Financial Officer |
Convert↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2025. The stock option vests twenty-five percent (25%) on January 28, 2026 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on such vesting date. |
Stock Option (Right to Buy)
|
47,000 |
| 2026-05-06 | VARKI PAUL |
Chief Legal Officer |
Convert↑
Filing footnotes — Common Stock (Direct)
The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2025. |
Common Stock
|
12,563 |
| 2026-05-06 | Doyle Mittie |
Director |
Convert↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025. The stock option vests twenty-five percent (25%) on January 28, 2026 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on each such vesting date. |
Stock Option (Right to Buy)
|
28,650 |
| 2026-05-06 | Doyle Mittie |
Director |
Convert↑
Filing footnotes — Common Stock (Direct)
The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025. |
Common Stock
|
77,905 |
| 2026-05-06 | VARKI PAUL |
Chief Legal Officer |
Convert↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2025. Twenty-five percent (25%) of the Option Shares vest on June 24, 2025 and the remainder of the Option Shares will vest in equal monthly installments on the first day of each month thereafter over the following three (3) years, provided that Optionee remains an employee of the Company on each such vesting date. |
Stock Option (Right to Buy)
|
62,500 |
| 2026-05-06 | Doyle Mittie |
Director |
Sell↓
Filing footnotes — Common Stock (Direct)
The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025. The reported securities were sold in multiple transactions at prices ranging from $18.00 to $18.97. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. |
Common Stock
|
27,538 |
| 2026-05-06 | VARKI PAUL |
Chief Legal Officer |
Convert↑
Filing footnotes — Common Stock (Direct)
The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2025. |
Common Stock
|
62,500 |